An official website of the United States government
Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer
Trial Status: active
This study is a first-in-human, Phase 1, open-label, multicenter study to assess the
safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary
efficacy of JANX014 in adults with metastatic castration-resistant prostate cancer
(mCRPC).
Inclusion Criteria
Male ≥18 years of age at the time of signing informed consent
Histologically or cytologically confirmed adenocarcinoma of the prostate
For Dose Escalation: Having mCRPC that progressed after at least one novel anti-androgen therapy and at least one taxane containing regimen. Participants who have actively refused a taxane containing regimen or are medically unsuitable to receive taxane are eligible.
Adequate organ function
For Dose Expansion Part: Have received ≤ 2 anti-androgen therapies in either the HSPC or CRPC setting and no more than 1 prior taxane regimen in the HSPC setting. Participants who have actively refused a taxane regimen or are medically unsuitable to receive taxane are eligible.
Exclusion Criteria
Prior solid organ transplant
Prior treatment with any CAR-T cell therapy, approved or investigational T-cell engager therapy, and prior receipt of radioligand therapy
Clinically significant cardiovascular disease
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT07545811.
